Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$1.45 – $2.30
39% from low
Exchange
OTC Link
ADRC
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $6.77B | $7.05B | $7.00B | $7.60B | $7.95B | $7.32B | $8.56B | $8.39B |
| Cost of revenue | $2.88B | $2.53B | $2.48B | $3.16B | $3.35B | $2.78B | $3.37B | $3.38B |
| Gross profit | $3.89B | $4.52B | $4.51B | $4.44B | $4.60B | $4.54B | $5.18B | $5.01B |
| Gross margin | 57.4% | 64.2% | 64.5% | 58.4% | 57.8% | 62.0% | 60.6% | 59.7% |
| R&D | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating income | $749.2M | $1.50B | $1.75B | $1.15B | $668.9M | $130.4M | −$1.00B | −$415.2M |
| EBITDA | $930.6M | $1.66B | $1.94B | $1.52B | $1.10B | $656.4M | −$545.6M | −$205.9M |
| Net income | $554.0M | $1.08B | $1.31B | $1.01B | $611.4M | $325.3M | −$749.3M | −$328.4M |
| Net margin | 8.2% | 15.3% | 18.7% | 13.4% | 7.7% | 4.4% | -8.8% | -3.9% |
| EPS (diluted) | 2.40 | 0.95 | 1.30 | 0.85 | 0.55 | 0.29 | -0.70 | -0.31 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $8.8B | $0.00 | $0.00–$0.00 | 0 |
| 2027 | $9.0B | $0.00 | $0.00–$0.00 | 0 |
Forward consensus · source: Financial Modeling Prep
BLUE MOON GRP UNSP/ADR
No one on the platform currently holds BLUMY.
No tracked institution reports a position in BLUMY as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-05-29 | $0.0637 | 2026-06-26 |
| 2025-09-17 | $0.0411 | 2025-10-15 |
| 2025-06-12 | $0.0306 | 2025-07-08 |
| 2024-09-10 | $0.0257 | 2024-10-07 |
| 2024-06-13 | $0.0384 | 2024-07-09 |
No one on the platform has traded BLUMY yet.
| +0.00% |
| $3.2B |
| — |
| KBYPFKobayashi Pharmaceutical Co., Ltd. | $34.05 | +0.00% | $2.5B | — |
| LIOPFLion Corporation | $11.51 | +0.00% | $3.2B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.